Abstract: The invention described herein includes a novel platform for the development of novel shapeshifting drug-like compounds that overcome physical mass limitations as they possess the ability to interconvert internally and spontaneously, i.e., shapeshift, between multiple chemical structures with varying pharmacophore properties. In one preferred embodiment, the invention include systems, methods, and compositions for the synthesis of novel bullvalene amino acid (Bvas) compounds that may further be incorporated into Shape Shifting Cyclic Peptides (SSCP) with varying pharmacophore properties and their use as novel therapeutic compounds.

Abstract: The invention described herein includes a novel platform for the development of novel shapeshifting drug-like compounds that overcome physical mass limitations as they possess the ability to interconvert internally and spontaneously, i.e., shapeshift, between multiple chemical structures with varying pharmacophore properties. In one preferred embodiment, the invention include systems, methods, and compositions for the synthesis of novel bullvalene amino acid (Bvas) compounds that may further be incorporated into Shape Shifting Cyclic Peptides (SSCP) with varying pharmacophore properties and their use as novel therapeutic compounds.

Abstract: The disclosure includes a method of inhibiting a eukaryotic translation initiation factor 3e (eIF3e) comprising contacting the eIF3e with a compound or salt of the Formula I, where the variables, e.g., Y, Z, R, and R1R11 are defined herein. The disclosure includes a method of modulating SIX1 and/or EYA2 levels or inhibiting SIX1/EYA2 interactions comprising contacting eukaryotic translation initiation factor 3e (eIF3e) with a compound of the formula. The disclosure includes a method of treating metastatic breast cancer (of all subtypes), glioblastoma, Wilms' tumor, ovarian cancer, lung cancer, cervical, oral cancer, or any cancer shown to be dependent on SIX1 or EYA proteins, which are regulated by eIF3e, in a patient comprising administering the patient a compound of the Formula I.

Abstract: The invention described herein includes a novel platform for the development of novel shapeshifting drug-like compounds that overcome physical mass limitations as they possess the ability to interconvert internally and spontaneously, i.e., shapeshift, between multiple chemical structures with varying pharmacophore properties. In one preferred embodiment, the invention include systems, methods, and compositions for the synthesis of novel bullvalene amino acid (Bvas) compounds that may further be incorporated into Shape Shifting Cyclic Peptides (SSCP) with varying pharmacophore properties and their use as novel therapeutic compounds.

Abstract: Provided are FRET-based biosensor constructs, and multiplexed platforms or arrays of these biosensor constructs useful for screening candidate drug molecules for efficacy and/or specificity of drug activity. Optionally the biosensor constructs may be located on an inner membrane within a cell or engineered to be located on the cell's surface. The cells or cell lines displaying the biosensors on a cell surface may be arranged as an array of cells for high throughput evaluation of the efficacy and/or specificity of drug candidates, such as a library of candidate drug compounds.

Abstract: Crosslinking compounds for effective and efficient cross-linking and identification of intermolecular and intramolecular interactions of proteins, peptides and nucleic acids.

Abstract: The invention includes the use of cannabidiol (CBD), and cannabidiol analogs, as therapeutic compounds or formulations for the increase of lipid order in the cell membranes of a patient. This increase in membrane lipid order may cause downstream therapeutic effects that may ameliorate certain disease conditions such as cardio vascular disease, high-cholesterol and Alzheimer's disease.

Abstract: Provided are FRET-based biosensor constructs, and multiplexed platforms or arrays of these biosensor constructs useful for screening candidate drug molecules for efficacy and/or specificity of drug activity. Optionally the biosensor constructs may be located on an inner membrane within a cell or engineered to be located on the cell's surface. The cells or cell lines displaying the biosensors on a cell surface may be arranged as an array of cells for high throughput evaluation of the efficacy and/or specificity of drug candidates, such as a library of candidate drug compounds.

Abstract: The invention relates to thermal shift assays implemented to uncover ligand protein binding interactions in whole cells or cell extracts. In particular embodiments, the invention provides improved methods and devices for performing thermal shift assays for determining both drug targets and drug mechanism of action. For example, the invention performs thermal shift assays in microfluidic devices and determines ligand-protein binding by relative protein abundance measurements.

Abstract: Crosslinking compounds for effective and efficient cross-linking and identification of intermolecular and intramolecular interactions of proteins, peptides and nucleic acids.

Abstract: Crosslinking compounds for effective and efficient cross-linking and identification of intermolecular and intramolecular interactions of proteins, peptides and nucleic acids.

Abstract: Methods, systems and recordable media for viewing large data sets having extremely disproportional dimensions on a symmetrical display. Data sets in matrix form having many more rows than columns or vice versa may be manipulated to make maximum use of a symmetrical display. Further data management processes facilitate navigation through large datasets and provide the ability to look at one or more portions of the data set in detail while still maintaining the context of the entire data set, or a larger portion of the dataset.

Abstract: Methods, systems and computer readable media for identifying peaks in a three-dimensional mass spectrometry/elution time dataset. The dataset is represented as a matrix of intensity values with column and row positions corresponding to specific elution time and m/z value, respectively. Peaks may be detected using a watershed image segmentation technique. Further provided are methods, systems and recordable media for creating a mask matrix to be overlaid on a large three-dimensional dataset represented as an image matrix, to identify a much smaller portion of the three dimensional dataset of interest, and to greatly reduce the amount of subsequent processing required for processing data of interest. The mask matrix has the same dimension as the image matrix and includes areas corresponding to one or more peaks identified by the watershed segmentation technique.